Greek
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Journal of Maternal-Fetal and Neonatal Medicine 2019-Aug

The effects of progesterone therapy in pregnancy: vaginal and intramuscular administration.

Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
Ο σύνδεσμος αποθηκεύεται στο πρόχειρο
Sedigheh Hantoushzadeh
Mahdi Sheikh
Mamak Shariat
Roodabeh Mansouri
Azin Ghamari
Fatemeh Golshahi

Λέξεις-κλειδιά

Αφηρημένη

Aim: This study was performed to evaluate the effects of vaginal versus intramuscular progesterone supplementations on the mood, quality of life, and metabolic changes in pregnant women with the history of previous preterm birth. Methods: This study was conducted as a prospective, randomized, open label, clinical trial evaluated 100 pregnant women who referred for prenatal visit, with 16-17 weeks of gestation from September 2014 through October 2015. The mothers were then randomly allocated into two groups: the vaginal progesterone group to receive 400 mg cyclogest vaginal suppositories (Actavis, UK limited, England) once daily, and the intramuscular progesterone group to receive weekly intramuscular injections of 250 mg of 17-hydroxyprogesterone caproate (17-HPC) (Bayer Schering Pharma, Germany), starting from the 16th to the 35th weeks of pregnancy. Demographics, medical and obstetrical history, sleeping disturbances, alteration in sexual desire, nausea/vomiting, serum levels of fasting blood sugar (FBS), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) were evaluated, first and 8 weeks later. Results: About 11 (11.2%) screened positive for psychosocial disorders; 25 (25.5%) had sleep disturbance, 11 (11.2%) had alteration in sexual desire, and 29 (29.6%) had nausea/vomiting upon enrollment. After 2 months of receiving daily vaginal progesterone, there was a significant increase in the GHQ-28 score (p < .001), and rates of positive screening for psychosocial disorders (p = .001) in this group. No statistically significant differences were observed in the HDL levels (p = .06), LDL levels (p = .15), rates of impaired FBS (p = .08), nausea/vomiting (p = .2), sexual desire alteration (p = .56), and sleep disturbance (p = 1) in the participants who were randomized to this group. Conclusion: Our results indicated that psychosocial disorders increased significantly at 24th week gestational age after 2 months of progesterone consumption in both groups which could show psychological impact of progesterone regardless of the route of consumption. This calls for higher psychological attention in these women.

Γίνετε μέλος της σελίδας
μας στο facebook

Η πληρέστερη βάση δεδομένων φαρμακευτικών βοτάνων που υποστηρίζεται από την επιστήμη

  • Λειτουργεί σε 55 γλώσσες
  • Βοτανικές θεραπείες που υποστηρίζονται από την επιστήμη
  • Αναγνώριση βοτάνων με εικόνα
  • Διαδραστικός χάρτης GPS - ετικέτα βότανα στην τοποθεσία (σύντομα)
  • Διαβάστε επιστημονικές δημοσιεύσεις που σχετίζονται με την αναζήτησή σας
  • Αναζήτηση φαρμακευτικών βοτάνων με τα αποτελέσματά τους
  • Οργανώστε τα ενδιαφέροντά σας και μείνετε ενημερωμένοι με την έρευνα ειδήσεων, τις κλινικές δοκιμές και τα διπλώματα ευρεσιτεχνίας

Πληκτρολογήστε ένα σύμπτωμα ή μια ασθένεια και διαβάστε για βότανα που μπορεί να βοηθήσουν, πληκτρολογήστε ένα βότανο και δείτε ασθένειες και συμπτώματα κατά των οποίων χρησιμοποιείται.
* Όλες οι πληροφορίες βασίζονται σε δημοσιευμένη επιστημονική έρευνα

Google Play badgeApp Store badge